Eli Lilly and Company (LLY MU) stock market data APIs
€907.3448
0(0%)
as of December 19, 2025
Try our APIs with
free plan!
Eli Lilly and Company Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for LLY.MU.
Prev. Close
907.3448
Open
907.3448
High
907.3448
Low
907.3448
52 wk Range
536.1268-960.5
Market Cap
206 794 M
EPS
3.34
Dividends (Yield)
0.0148
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Eli Lilly and Company data using free add-ons & libraries
Get Eli Lilly and Company Fundamental Data
Eli Lilly and Company Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-01
- EPS/Forecast: 3.03
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Eli Lilly and Company News
New
Pharma's $370B Bet on America: The ETF Plays for 2026
The U.S. pharmaceutical industry underwent a historic, policy-driven transformation in 2025. After a period of post-pandemic cooling, the industry demonstrated stark improvement, ignited by a complex ...
White House Will Announce Pricing Deals With More Drugmakers Friday
The Trump administration has talked tough about cutting drug prices, but the impacts of the deals with drug companies announced thus far have been limited. Continue Reading
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Pfizer PFE stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations. Pfizer expects total revenues for 202...
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
Novo Nordisk NVO announced the submission of a new drug application (NDA) to the FDA, seeking approval for its next-generation once-weekly injection, CagriSema, to reduce excess body weight and mainta...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
